The US Preventive Services Task Force (USPSTF) has updated its recommendations regarding the efficacy of supplements or multivitamins for reducing the risk of cardiovascular disease, cancer, and mortality in the general adult population.
The USPSTF concluded there is insufficient
Read Article
Aside from cost, there are significant concerns regarding efficacy and safety outcomes and recovery time. These issues are compounded with the need for bilateral TKR, wherein the patient and surgeon need to decide whether to have both TKRs done simultaneously or staged (single TKR one after
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium.
Read Article
Links:
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.
Risk factors for readmission among 132,400 #SLE hospitalizatiions included
A crowd sourced, WikiGuidelines approach to clinical treatment guideline development for pyogenic osteomyelitis yielded 7 important clinical questions, 2 clear treatment recommendations and 5 topic reviews to inform future treatment or investigations.
Some clinical scenarios may be
Read Article
Mayo Clinic Proceedings reports the results of a retrospective, cross-sectional of patients with HFE hemochromatosis showing that advanced hepatic fibrosis is primarily seen in those with arthritis due to HFE hemochromatosis.
A total of 112 patients with a liver biopsy confirmed
Read Article
TheDaoIndex @KDAO2011( View Tweet )
Links:
The ACR has updated its clinical guidelines for the management of juvenile idiopathic arthritis (JIA), with this update focusing on oligoarthritis, TMJ arthritis, and systemic JIA (with and without macrophage activation syndrome); only the latter, systemic JIA recommendations are reported
Read Article
A pragmatic, open-label trial of osteoarthritis (OA) patients demonstrated that adding duloxetine treatment seems to be beneficial for end-stage knee OA patients with neuropathic-like symptoms (at risk of central sensitization).
While duloxetine is approved for the treatment of
Read Article
Links:
Osteoarthritis (OA) of the hand was less severe according to objective and pain-related markers in Black patients versus those of other racial/ethnic groups after adjustment for known risk factors, researchers found.
The finding was a major surprise and somewhat mysterious, insofar as
Read ArticleLinks:
Dr. John Cush @RheumNow( View Tweet )
Links:
The July 2021 RheumNow “Live Vote” surveyed US and non-US rheumatologists on their knowledge and practices when dealing with the bone disorder, X-linked hypophosphatemia (XLH). Although rare, XLH can be a diagnostic consideration in patients with recurrent fractures, rickets, osteomalacia and
Read Article
Links:
While bisphosphonate drug holidays are recommended, there are few comparative studies. Annals of Internal Medicine describes a propensity matched comparison study of risedronate and alendronate, showing that, compared to alendronate, risedronate drug holidays were associated with a small
Read ArticleIt's great to be a rheumatologist, but boy, it's getting harder and harder. You have to be a jack of all trades. You have to be good at cardiovascular disease, osteoporosis, vaccination, inflammatory bowel disease - it just never ends. This and more, as Dr. Cush summarizes more than a dozen
Read ArticleDr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.
Read Article
EULAR has published evidence-based recommendations on the use of intra-articular therapies (IAT) based on the literature review and recommendations of a multidisciplinary international task force. These IAT recommendations apply to adult patients with peripheral arthropathies.
The
Read ArticleLinks:
Dr. John Cush @RheumNow( View Tweet )
Links:
Links:
